Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
F-star Therapeutics Ltd (F-star Therapeutics), formerly F-star Therapeutics Inc, is a clinical-stage biopharmaceutical company that develops novel, innovative tetravalent bispecific antibodies for cancer and serious illnesses. The company’s pipeline products include FS118, FS120, FS222, and SB 11285. Its pipeline candidates treat rescuing clinical practice improvement (CPI) treatment failures and improving outcomes in the clinical practice improvement (CPI) naive, improving outcomes in programed cell death ligand 1 (PD-L1) low tumors, and improving CPI and chemotherapy outcomes. F-star Therapeutics partner programs include multiple blood-brain barriers, multiple immuno-oncology, STING inhibitors, and multiple next-generation bispecific antibodies. It operates in the UK and the US. It is a subsidiary of invoX Pharma Ltd. F-star Therapeutics is headquartered in Cambridge, England, the UK.
Headquarters
United Kingdom
Address
Eddeva B920, Babraham Research Campus, Cambridge, England, CB223AT
Website
www.f-star.com
Telephone
44 1223 497400
No of Employees
35
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$14.2M
F-star Therapeutics Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| SB 11285- Improving Clinical Practice Improvement (CPI) Outcomes |
| FS118- Rescuing Clinical Practice Improvement (CPI) Treatment Failures and Improving Outcomes in Clinical Practice Improvement (CPI) Naive |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | F-star Therapeutics Ltd | Kymab Ltd | Scancell Holdings Plc | Fusion Antibodies Plc | Mission Therapeutics Ltd |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United Kingdom | United Kingdom | United Kingdom |
| City | Cambridge | Cambridge | Oxford | Belfast | Cambridge |
| State/Province | England | England | Oxfordshire | Northern Ireland | Cambridgeshire |
| No. of Employees | 35 | 148 | 60 | 24 | 30 |
| Entity Type | Private | Private | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Neil Douglas Brewis, Ph.D. | Director; Chief Scientific Officer | Executive Board | 2023 | 60 |
| Ryan William Fiehler, Ph.D. | Head; Director | Executive Board | 2025 | 51 |
| Katy Everett | Head - Discovery | Senior Management | - | - |
| Pauline Stevens | Head - Operations | Senior Management | - | - |
| Thomas Gallagher | Head - Data Science | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer